Lxxviii

•Download as PPTX, PDF•

0 likes•119 views

The document contains a single line with the number "LXXVIII", followed by a name "Fanny Dávila Guida" and a class designation "10-B.". In just a few words and numbers, this brief document identifies a person and their class.

OutsideIn Research is an affiliate of The ProActive Network that publishes high-quality company research reports and industry studies written by our staff of very experienced Wall Street and buy-side analysts. Our approach is to provide investors with the necessary tools and information with which to make sound investment decisions. We attempt to distill and present the essential facts of the company and avoid some of the trappings of most Wall Street.

Rodman & Renshaw - $VTUS May 2011 Update

ProActive Capital Resources Group

DARA BioSciences, Inc (NASDAQ: DARA) is a pharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept (pre-phase III) in humans for subsequent sale or out-licensing to larger pharmaceutical companies. KRN5500* for the treatment of neuropathic pain in patients with cancer – successfully completed a phase II study. KRN5500 met its primary endpoints of reduction of pain and safety. It was statistically significantly better than placebo (p=0.03). The company plans to initiate a second phase II this year in conjunction with the National Cancer Institute focusing on the treatment and prevention of chemotherapy induced peripheral neuropathy (CIPN). The NCI will sponsor these studies with DARA only having to supply active drug and placebo.